The Otsuka Group's pharmaceutical business focuses on the core areas of the central nervous system and oncology in order to address unmet medical needs. Additionally, the Group is engaged in a wide range of other fields and businesses, including the cardiovascular system, gastroenterology, ophthalmology, diagnostics, and the clinical nutrition and medical device businesses in order to provide comprehensive healthcare solutions ranging from diagnosis to the treatment of disease.
Otsuka Pharmaceutical has been actively developing pharmaceuticals for the global market ever since the establishment of a research and development division in 1971. The company is constantly focused on resolving medical issues associated with curing disease and improving the quality of life (QOL), aspiring to develop innovative pharmaceuticals to aid in treating disorders of the central nervous system; cancer; cardiovascular, gastrointestinal and respiratory ailments; infectious diseases; and in the areas of ophthalmology and dermatology. New drug development is also progressing in the fields of Agitation associated with dementia of the Alzheimer's type and Chronic/Acute myeloid leukemia.
Based on a global strategy for the development and commercialization of pharmaceuticals, preclinical research is conducted in Japan, the US and China, while clinical development occurs mainly in Japan, the US, Europe and Asia, utilizing an extensive network of research facilities both within and outside Japan for global research and development.
Taiho Pharmaceutical conducts pharmaceutical research and development specializing in the areas of oncology, allergy/immunology, and urology. The company has Discovery and Preclinical Research Division (Tsukuba Area) as base for drug discovery research which has created a research network closely coordinated with the Discovery and Preclinical Research Division (Tokushima Area) and the Clinical Development Division in order to establish an R&D system focused on new medical treatment. In the field of oncology, which is the company's foremost field of endeavor, Taiho Pharmaceutical carries out global development of its mainstay anticancer agents in Japan, the U.S., Europe and Asia and engages in R&D with the aim of providing innovative new drugs to the world.
Otsuka Pharmaceutical Factory
In addition to IV solutions, our core product domain and a fundamental pillar of medical treatment, and medical foods, we engage in R&D to develop products which create new value by meeting unmet needs in the fields of surgical aid and regenerative medicine products. We see things from the patient's point of view and develop innovative medical products which are not bound by the constraints of existing concepts, and undertake all these initiatives with enthusiasm and a sense of duty. For example, we are developing a product to prevent adhesions, a common cause of abdominal pain and intestinal obstruction after operations, and a bioengineered pancreatic islet product which could become a major treatment for diabetes patients.